Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 36 for “"BCR-ABL"”.
-
Src-Kinasen als Mediatoren Bcr-Abl-induzierter Leukämien
Bcr-Abl, eine onkogene Tyrosinkinase, ist maßgeblich an der Entstehung der chronischen myeloischen Leukämie (CML) sowie einem Teil der Fälle von akuter B-lymphoblastischer Leukämie (B-ALL) beteiligt. Die essentielle Rolle der Kinase-Aktivität von Bcr-Abl für dessen leukämogenes Potential konnte in …
-
The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia
… following generation of the chimeric protein Bcr-Abl, a constitutively active tyrosine kinase which induces oncogenesis in part by promoting increased cell survival and proliferation. Since the development of Bcr-Abl-specific tyrosine kinase inhibitors (TKIs) there has been a substantial …
-
Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia
… signaling by the Philadelphia chromosome-encoded BCR-ABL fusion kinase initiates and drives both Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Food and Drug Administration (FDA)- approved BCR-ABL-specific kinase inhibitors …
-
Bedeutung der Rezeptor-Tyrosinkinase c-Kit in der Pathogenese der, Philadelphiatranslokation Bcr-Abl positiven, chronischen myeloischen Leukämie
… Rezeptor-Tyrosinkinase c-Kit mit dem Onkoprotein Bcr-Abl. Es wird in der zeitlichen Abfolge der chronisch myeloischen Leukämie (CML) besonders für die chronische Phase eine Beteiligung des Stammzellfaktors (SCF), dem natürlichen Liganden von c-Kit, an der Proliferation des malignen Zellklons …
-
Biological Mechanisms and Clinical Implications of Bcr-Abl-Induced Mitochondrial Oxidative Stress and Cell Survival In Chronic Myeloid Leukemia
… constitutively active protein-tyrosine kinase BCR-ABL, which is encoded by <em>BCR-ABL</em> fusion gene as the result of chromosome 9/22 translocation (Philadelphia chromosome). Previous studies have demonstrated that oxidative stress-associated genetic, metabolic and biological alterations …
-
Vitamin D Levels Affect Survival in a BCR-ABL Acute Lymphoblastic Leukemia Mouse Model but Do Not Cause Vitamin-Drug Interactions
<p>It is a well-established phenomenon that dietary components containing CYP3A inducers or inhibitors if co-administered with drugs that are CYP3A4 substrates lead to marked drug-drug interactions. Because vitamin D is known to regulate intestinal CYP3A expression and gut CYP3A expression plays an …
-
Proteasome inhibition in chronic myeloid leukaemia
… CM HSC to TKI and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and PI are cytotoxic against CML cell lines. We demonstrate that bortezomib is antiproliferative and induces apoptosis in CD34+ cells taken at diagnosis from …
-
Substratspezifität und Signaltransduktion zellulärer und onkogener Abl-Tyrosinkinasen
… Überaktivierung von Tyrosinkinasen der Abl-Familie spielen eine wesentliche Rolle in verschiedenen Leukämieformen beim Menschen. Neben der schon seit vielen Jahren für die CML als ursächlich anerkannten Fusionskinase p210Bcr-Abl sind weitere Fusionskinasen unter Beteiligung der …
-
Proteogenomic Insights Into The Nature Of Chemoresistance In Chronic Myelogenous Leukemia
… chromosome, a reciprocal translocation of the ABL1 oncogene on chromosome 9, and the breakpoint cluster region gene (BCR) chromosome 22, resulting in the BCR-ABL oncoprotein. BCR-ABL is a constitutively active tyrosine kinase that regulates cell growth and differentiation, leading to …
-
Overcoming Tumor Drug Resistance By Activating Amp-Activated Protein Kinase And Destabilizing Oncoproteins
<p>Although considerable progress has been achieved in the field of cancer therapeutics, primary or acquired drug resistance remains a fundamental cause of therapeutic failure in cancer therapy. Among different mechanisms characterized that are responsible for tumor drug resistance, there is …
-
Coordinate regulation of Vegf signalling genes by the proline rich homeodomain protein
… nuclear retention of PRH. The oncogenic BCR-ABL fusion protein increases CK2 activity. I show that Inhibition of BCR-ABL in CML cells results in decreased PRH phosphorylation and the down-regulation of PRH target genes. Reestablishment of gene control by PRH is partly responsible for the …
-
Investigating a co-operative link between TGF-β and Lyn kinase in Chronic Myeloid Leukaemia
… haematopoietic cells driven by the fusion gene Bcr-Abl. The advent of a mechanism specific kinase inhibitor, Imatinib, targeting the constitutively active Bcr-Abl kinase has paved the way for new treatment strategies. However, resistance emerges, particularly in those in more advanced disease …
-
A chromatin-modifying protein is a context-dependent modulator of cell survival in hematopoietic malignancies
… disease progression may result in more amenable drug targets. With this in mind, our group carried out a large-scale RNA interference (RNAi) screen for factors influencing disease progression in a murine model of BCR-Abl+ B-ALL, a disease with low long-term survival rates despite treatment …
-
Development of an RNA aptamer to PD173955N through SELEX
<p>With all the technology available to us, the causes of cancers are still puzzling researchers all over the world. Everyday different approaches are being tested to help cure various cancers. With the development of molecular biology, we are able to understand cancer more at molecular level, …
-
Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase.
… translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the …
-
Autophagy in Metabolism, Cell Death, and Leukemogenesis
… constitutively active oncogenic kinases such as BCR-Abl that promote these processes independent of extrinsic growth factors. When cells are deprived sufficient growth signals or when oncogenic kinases are inhibited, glucose metabolism decreases and cells activate the self-digestive process of …
-
Expression and function of drug transporters in primitive CML cells
… expression of the oncogenic fusion protein BCR-ABL. The current first line of treatment is imatinib mesylate (IM), a tyrosine kinase inhibitor (TKI) that competes with ATP to block ABL kinase activity, which in turn prevents tyrosine phosphorylation of downstream molecules and selectively …
Page 1 of 2